Volume 1 · Issue 3 · June 2026
The new NutriCellScience Monthly Review is out. This June issue follows a single thread: the molecules that speak to our cells — from autophagy to postbiotics — carefully separating what the evidence shows from what the marketing claims.
The molecules that speak to our cells
As always, two reading levels coexist: an accessible main text for the informed general reader, and professional call-outs for healthcare practitioners (levels of evidence, references, weak signals).
In this issue
- Biohacking & Longevity — spermidine and autophagy, senolytics (D+Q, fisetin), NMN/NR meta-analyses, rapamycin (the PEARL trial). Weak signal: the 11 compounds with no effect in the NIH Interventions Testing Program, and the NARB’s recalibration of Tru Niagen claims.
- Supplements & Ergogenic Performance — the ISSN position stand on astaxanthin and omega-3, creatine, caffeine gum, ashwagandha, beta-alanine. Weak signal: the 2026 WADA Prohibited List and the FDA alert on yellow oleander.
- Microbiota & Digestive Health — repeated FMT in Parkinson’s disease, a multi-strain probiotic for constipation, the Akkermansia/cancer axis, F. prausnitzii and the gut-lung axis, the sulforaphane bridge. Weak signal: the 2026 EFSA QPS opinion and the GutMIND project.
Download the review (PDF, 6 pages)
Note: the downloadable PDF is in French. An English-language edition of the full review is in preparation.
Version française : Revue Mensuelle — Juin 2026
NutriCellScience — Mark DOWN
Laisser un commentaire